Labiotech.eu

lupus autoimmune disease neutrophil citryll

News and Trends 16 Sep 2022

Domainex’ drug shows positive data for treatment of interferonopathies

Interferonapathies such as lupus, Sjögren’s syndrome, and scleroderma could be treated effectively after positive human ex-vivo data was produced. Domainex Ltd., carried out an in-house research program to identify inhibitors of protein kinases TBK1 and IKK-epsilon and DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. Disease modifying The […]

September 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Sep 2022

Beyond Biotech podcast 14: Nordic Life Science NLS Days 2022

This week’s podcast is dedicated to Nordic Life Science Days, otherwise known as NLS Days. This year’s version is an in-person event from September 28-29, at the Malmömässan in Malmö, Sweden. In our preview of NLS Days, which features sessions and fireside chats, company presentations, an exhibition, and one-on-one partnering meetings, we have interviews with […]

September 16, 2022

News and Trends 16 Sep 2022

CHMP recommends approval of Beyfortus for prevention of RSV disease in infants

Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of RSV lower respiratory […]

September 16, 2022 - 4 minutesmins - By Jim Cornall

Startup Scout 15 Sep 2022

Adva Biotechnology is using artificial intelligence to manufacture cell therapies

The manufacturing of cell therapies is highly complex, often depending on skilled manual labor. The Israeli startup Adva Biotechnology aims to use automation, optical sensing and artificial intelligence to remove the manual component from the process. Cancer cell therapies such as CAR-T immunotherapies have demonstrated enormous potential for treating forms of blood cancer. Currently available […]

September 15, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 15 Sep 2022

Novome Biotechnologies raises $43.5M for therapeutically engineered microbes pipeline

U.S. biotech company Novome Biotechnologies, Inc., has closed a $43.5 million series B financing round. The financing was led by Tencent, and includes new investors University of Minnesota, Navian Investments, Colorcon Ventures and Touchdown Ventures. Existing investors DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments also participated. The proceeds will be used to […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Sep 2022

So much data – Spanish researchers develop The Bioteque to pool biological knowledge

There’s a lot of research going on around the world, and that means lots of data. On a personal level, we’ve seen computer hard drives jump in memory constantly to keep pace with all of the information, bigger images, and so on. Many people have an external drive with 1TB (terabyte) or 2TB of storage. […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Sep 2022

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF

The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

Prothena, Parkinsons Disease, neurons, neurological diseases

News and Trends 15 Sep 2022

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

PBC clinical trials: Gannex doses first patient

News and Trends 15 Sep 2022

Tridek-One brings in €16M to develop auto-immune diseases candidates

Tridek-One SAS, a French biotech startup specialized in the research and development of CD31 agonists to restore immune balance, has closed a €16 million ($16.1 million) new financing round. The financing was led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures, as well as historical investors AdBio partners and […]

September 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Sep 2022

New company formed to boost life sciences in Singapore

ClavystBio, a company established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek, has launched, with its mission to accelerate the commercialization of life sciences discoveries and innovation in Singapore. The life sciences sector is set to be a key driver of Singapore’s future economy. The sector currently employs 25,000 workers and contributes to […]

September 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Recursion adds FAP and C. diff clinical trials

Recursion Pharmaceuticals has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. The phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule […]

September 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering

Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Domainex’ drug shows positive data for treatment of interferonopathies

Beyond Biotech podcast 14: Nordic Life Science NLS Days 2022

CHMP recommends approval of Beyfortus for prevention of RSV disease in infants

Adva Biotechnology is using artificial intelligence to manufacture cell therapies

Novome Biotechnologies raises $43.5M for therapeutically engineered microbes pipeline

So much data – Spanish researchers develop The Bioteque to pool biological knowledge

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Tridek-One brings in €16M to develop auto-immune diseases candidates

New company formed to boost life sciences in Singapore

Recursion adds FAP and C. diff clinical trials

Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!